Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.

Luis A. Diaz,Dung T. Le,Tae-Won Kim,Eric Van Cutsem,Ravit Geva,Dirk Jaeger,Hiroki Hara,Matthew Burge,Bert H. ONeil,Petr Kavan,Takayuki Yoshino,Rosine Guimbaud,Hiroya Taniguchi,Elena Elez,Salah-Eddin Al-Batran,Patrick M Boland,Yi Cui,Carlos Alberto Mayo,Patricia Marinello,Thierry André

Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.

2020

4032Background: Pembrolizumab provides effective antitumor immunity and durable responses in patients (pts) with advanced, colorectal cancer (CRC) with microsatellite instability-high (MSI-H) tumor...

Keywords:

Oncology
Colorectal cancer
Pembrolizumab
Pathology
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations